Skip to Content

Tindamax (tinidazole) Disease Interactions

There are 5 disease interactions with Tindamax (tinidazole):

Major

Nitroimidazoles (Includes Tindamax) ↔ Blood Dyscrasias

Severe Potential Hazard, Low plausibility

Applies to: Bone Marrow Depression/Low Blood Counts, History - Blood Dyscrasias

The use of nitroimidazoles (e.g., metronidazole, tinidazole) has rarely been associated with hematologic adverse effects such as mild, transient leukopenia, thrombocytopenia, and bone marrow aplasia. The manufacturers recommend that therapy with nitroimidazoles be administered cautiously in patients with evidence of or a history of blood dyscrasias, and that total and differential leukocyte counts be performed before and after treatment with these drugs, particularly in patients receiving repeated courses of therapy.

References

  1. White CM, Price JJ, Hunt KM "Bone marrow aplasia associated with metronidazole." Br Med J 280 (1980): 647
  2. "Product Information. Flagyl (metronidazole)." Searle, Skokie, IL.
  3. "Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc, Arlington Heights, IL.
  4. Smith JA "Neutropenia associated with metronidazole therapy." Can Med Assoc J 123 (1980): 202
View all 4 references
Major

Nitroimidazoles (Includes Tindamax) ↔ Neurologic Toxicity

Severe Potential Hazard, Moderate plausibility

Applies to: CNS Disorder, Peripheral Neuropathy

The use of nitroimidazoles (e.g., metronidazole, tinidazole) has been associated with the development of nervous system toxicity including convulsive seizures and dose-related peripheral neuropathy, the latter characterized primarily by numbness or paresthesia of an extremity. Persistent peripheral neuropathy has been reported in some patients treated for prolonged periods. Other neurologic adverse effects include vertigo, incoordination, ataxia, confusion, agitation, hallucinations, and depression. Therapy with nitroimidazoles should be administered cautiously in patients with or predisposed to seizures or other nervous system abnormalities. Nitroimidazole therapy should be discontinued promptly if neurologic disturbances occur.

References

  1. "Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc, Arlington Heights, IL.
  2. "Product Information. Flagyl (metronidazole)." Searle, Skokie, IL.
  3. Schreiber W, Spernal J "Metronidazole-induced psychotic disorder." Am J Psychiatry 154 (1997): 1170-1
  4. Learned-Coughlin S "Peripheral neuropathy induced by metronidazole." Ann Pharmacother 28 (1994): 536
  5. Lawford R, Sorrell TC "Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report." Clin Infect Dis 19 (1994): 346-8
  6. Stahlberg D, Barany F, Einarsson K, Ursing B, Elmquist D, Persson A "Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole." Scand J Gastroenterol 26 (1991): 219-24
  7. Wienbren M, Perinpanayagam RM, Camba L, Lee CA "Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole." J Clin Pathol 38 (1985): 1076
  8. Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ "Central nervous sytem toxicity associated with metronidazole therapy." Ann Intern Med 93 (1980): 59-60
  9. Alvarez RS, Richardson DA, Bent AE, Ostergard DR "Central nervous system toxicity related to prolonged metronidazole therapy." Am J Obstet Gynecol 145 (1983): 640-1
  10. Ahmed A, Laes DJ, Bressler EL "Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy." Neurology 45 (1995): 588-9
  11. Boyce EG, Cookson ET, Bond WS "Persistent metronidazole-induced peripheral neuropathy." DICP 24 (1990): 19-21
  12. Schentag JJ, Ziemniak JA, Greco JM, Rainstein M, Buckley RJ "Mental confusion in a patient treated with metronidazole: a concentration-related effect." Pharmacotherapy 2 (1982): 384-7
  13. Duffy LF, Daum F, Fisher SE, et al "Peripheral neuropathy in Crohn's disease patients treated with metronidazole." Gastroenterology 88 (1985): 681-4
  14. Beloosesky Y, Grosman B, Marmelstein V, Grinblat J "Convulsions induced by metronidazole treatment for Clostridium difficile-associated disease in chronic renal failure." Am J Med Sci 319 (2000): 338-9
View all 14 references
Moderate

Metronidazole (Includes Tindamax) ↔ Alcoholism

Moderate Potential Hazard, Moderate plausibility

Applies to: Alcoholism

Nitroimidazoles (e.g., metronidazole, tinidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated. Symptoms may include nausea, vomiting, flushing, sweating, headache, abdominal cramps, and hypotension. Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 to 72 hours after the last dose. Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake. An alternative therapy may be appropriate.

References

  1. Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983): 509-15
  2. Harries DP, Teale KF, Sunderland G "Metronidazole and alcohol: potential problems." Scott Med J 35 (1990): 179-80
  3. Alexander I "Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment." Br J Clin Pract 39 (1985): 292-3
  4. "Product Information. Flagyl (metronidazole)." Searle, Skokie, IL.
  5. Williams CS, Woodcock KR "Do ethanol and metronidazole interact to produce a disulfiram-like reaction?." Ann Pharmacother 34 (2000): 255-7
  6. "Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc, Arlington Heights, IL.
View all 6 references
Moderate

Tinidazole (Includes Tindamax) ↔ Hemodialysis

Moderate Potential Hazard, High plausibility

Applies to: hemodialysis

Tinidazole is removed by hemodialysis. During a 6-hour hemodialysis session, approximately 43% of the drug present in the body is eliminated, and the half-life is reduced from 12 hours to 4.9 hours. Therefore, on days when dialysis is performed, an additional dose of tinidazole equivalent to one-half the prescribed dose is recommended after the hemodialysis session.

References

  1. Flouvat BL, Imbert C, Dubois DM, et al. "Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis." Br J Clin Pharmacol 15 (1983): 735-41
  2. "Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc, Arlington Heights, IL.
Moderate

Tinidazole (Includes Tindamax) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

There are no data on the pharmacokinetics of tinidazole in patients with impaired hepatic function. Reduction of metabolic elimination of metronidazole, a chemically-related drug, has been reported in patients with hepatic dysfunction. Since tinidazole is also extensively metabolized by the liver prior to excretion, therapy with tinidazole should be administered cautiously in the presence of severe liver disease.

References

  1. Wood BA, Faulkner JK, Monro AM "The pharmacokinetics, metabolism and tissue distribution of tinidazole." J Antimicrob Chemother 10 Suppl A (1982): 43-57
  2. "Product Information. Tindamax (tinidazole)." Presutti Laboratories Inc, Arlington Heights, IL.

Tindamax (tinidazole) drug Interactions

There are 193 drug interactions with Tindamax (tinidazole)

Tindamax (tinidazole) alcohol/food Interactions

There is 1 alcohol/food interaction with Tindamax (tinidazole)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide